Dr. Michael A. Stephens, MD
Family Medicine (Family Medicine Physician)
1008 Park Ave Ste A
Orange Park, FL 32073
Who else practices at this address →
Clay County includes primary care (9% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Miami, Lm Miller School of Medicine (1992)
- Years since graduation
- 34
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 1,343
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1992Medical school: University of Miami, Lm Miller School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
FL license ME64230
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baptist Health Medical Center - Jacksonville Jacksonville, FL
- Ascension St Vincent's Riverside Jacksonville, FL
- HCA Florida Orange PArk Hospital Orange PArk, FL
- Ascension St Vincent's Clay County Middleburg, FL
Medical groups
- Baptist Primary Care Inc (471 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,343
- Services billed
- 4,503
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 1,938 | 1,005 |
| Insertion of needle into vein for collection of blood sample | 1,179 | 819 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 436 | 436 |
| Established patient office or other outpatient visit, 20-29 minutes | 130 | 117 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 101 | 99 |
| Urinalysis, manual test | 97 | 81 |
| Administration of influenza virus vaccine | 80 | 79 |
| Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | 80 | 67 |
| Influenza vaccine split virus, preservative free | 76 | 75 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 73 | 25 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 84 payments worth $1,669 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $209 |
|---|---|
| AbbVie Inc. | $206 |
| Amgen Inc. | $194 |
| Bayer HealthCare Pharmaceuticals Inc. | $175 |
| Lilly USA, LLC | $117 |
| Novo Nordisk Inc | $112 |
| Pfizer Inc. | $95.46 |
| Lundbeck LLC | $78.88 |
| Food and Beverage | $1,669 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 6 companies. The companies reported $514,075 in research payments for these studies, mostly to the institutions running them.
- A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
Seqirus USA Inc · Completed · NCT06087640 - A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age
ModernaTX, Inc. · Completed · NCT05127434 - Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmon…
AstraZeneca Pharmaceuticals LP - LX9211.1-204-DPN
Lexicon Pharmaceuticals, Inc. - A phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like part…
AstraZeneca Pharmaceuticals LP - A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment
AstraZeneca UK Limited - A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of VX-548 in Subjects With Painful Lumbosacral Radiculopathy
Vertex Pharmaceuticals Incorporated
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.